A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according ...
A key opinion leader reviews findings presented at ID Week 2020 from a post-hoc analysis of the AMBER study comparing GI tolerability of D/C/F/TAF to TDF. Moti Ramgopal, MD, FACP, FIDSA, CPI: The ...
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen ...
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented three-year results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results